Rocket Lab USA, Inc. ( RKLB) stock is sinking today due to a combination of factors, primarily identified as rising investor concern over its flagship Neutron rocket development and broader market dynamics.
Even though the company has been posting solid growth and racking up successful launches, investors seem to be hitting pause. A hiccup in late-stage testing for the Neutron rocket has sparked fresh worries about delays, and that uncertainty is weighing on the stock. On top of that, money is flowing toward bigger names in the space industry, leaving Rocket Lab under added pressure.
Balancing Strong Financials Against Development Risks
The shares of RKLB fell in after-hours following the firm’s report of strong earnings for its fourth quarter of Fiscal Year 2025. The firm reported Earnings Per Share of $0.09, which missed the analyst’s consensus estimate of $0.10 per share. The stock’s sales also increased by 35.8% year-over-year, with the revenue hitting $179.65 million, which also exceeded the analyst’s expectation of $176.83 million. For the full year, Rocket Lab USA projected a revenue of $602 million, up 38% from the prior year.
— Rocket Lab (@RocketLab) February 27, 2026
The critical catalyst for the recent dip is a failure in a qualifying test for the Neutron rocket, which was a crucial project central to the long-term growth strategy of Rocket Lab. Rocket Lab was reported to be deep in the development of the Neutron rocket, which was expected to be a more powerful rocket than the Electron.
Sir Peter Beck, CEO of Rocket Lab USA, said that the Neutron is designed for mega-constellation deployment, deep space missions, and human spaceflight. This Neutron had a great potential for a wide range of uses, and that was the major hitch with it. While in the late-stage testing last month, the craft’s stage 1 fuel struggled with a rupture. Although it was designed to subject components to near-maximum adverse conditions, the outcome dealt a significant setback to the project.
This pullback has raised doubts about the timeline of the inaugural launch of the rocket, which was previously expected this year, but it is now likely delayed by several months, causing the stock to retreat from its high as investors reassess the firm’s near-term prospects.
Liquidity Shift Pressures Rocket Lab Shares
This year also witnessed a record of 21 launches from Rocket Lab, with a perfect mission success rate. Additionally, the firm secured an $816 million deal to build 18 missile-tracking satellites, which aided in driving a $1.85 billion backlog. However, the market sentiment and sector headwinds weighed on the stock. The anticipated $1.5 trillion SpaceX IPO drew capital away from rival space companies like Rocket Lab, contributing to a liquidity shift.
Adding to the dip, Rocket Lab’s proposed project, the 2031 Mars sample-return mission, has added company-specific pressures, despite not being able to be a driver of near-term revenue. Apart from this, Rocket Lab recently announced a new $750 million at-the-market (ATM) equity offering, which led to the sale of shares at prevailing market prices.
The stock is trading 6.2% below its 20-day simple moving average, signaling short-term weakness. Options trading data shows a steeper put-call skew, indicating rising demand for downside protection and growing caution among traders, even though call volumes still outpace puts. Despite the headwinds, the firm reported record revenue and a busy launch year. Furthermore, analysts are maintaining a moderate buy consensus rating with an average price target of $49.19.
